비용종을 동반한 만성비부비동염 환자에서 Dupilumab 치료 시 발생하는 부작용에 대한 후향적 연구
Adverse Events of Dupilumab Injection in Patients With Chronic Rhinosinusitis With Nasal Polyposis
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Objectives Chronic rhinosinusitis with nasal polyposis (CRSwNP) is onephenotype of the diffuse type. In spite of surgical and medical treatment, the polyp recurrencerate is high. Recently biologics are concerned as a therapeutic option of it. To figure out ad-verse events associated with the dupilumab injection in adult patients with CRSwNP. Subjects and Method Retrospective chart review of patients that were treated with dupil-umab from January 2022 to December 2022 for CRSwNP was performed. Results Of 40 patients (23 of male and 17 of female), 8 patients (20.0%) experienced 9 pa-tients (22.5%) adverse events. The most common adverse event was skin reaction (3 patients,7.5%), followed by 2 of pruritis, 2 of epistaxis. Three patients quit dupilumab after the adverseevents, 4 patients continued, and 1 patient hold the next injection. Conclusion Dupilumab is reported to be relatively safe medication. However, physicianshould notice that adverse events including skin rash can occur after dupilumab injection.
Abstract
Background and Objectives Chronic rhinosinusitis with nasal polyposis (CRSwNP) is onephenotype of the diffuse type. In spite of surgical and medical treatment, the polyp recurrencerate is high. Recently biologics are concerned as a therapeutic option of it. To figure out ad-verse events associated with the dupilumab injection in adult patients with CRSwNP. Subjects and Method Retrospective chart review of patients that were treated with dupil-umab from January 2022 to December 2022 for CRSwNP was performed. Results Of 40 patients (23 of male and 17 of female), 8 patients (20.0%) experienced 9 pa-tients (22.5%) adverse events. The most common adverse event was skin reaction (3 patients,7.5%), followed by 2 of pruritis, 2 of epistaxis. Three patients quit dupilumab after the adverseevents, 4 patients continued, and 1 patient hold the next injection. Conclusion Dupilumab is reported to be relatively safe medication. However, physicianshould notice that adverse events including skin rash can occur after dupilumab injection.
참고문헌 (10)
- Fokkens WJ, "EUFOREA consensus on biologics for CRSwNP with or without asthma", Allergy, 74(12), pp.2312~2319 (2019)
- Bhattacharyya N, "Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps", Laryngoscope, 129(9), pp.1969~1975 (2019)
- Le Floc’h A, "Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rαantibody, is required to broadly inhibit type 2 inflammation", Allergy, 75(5), pp.1188~1204 (2020)
- Fokkens WJ, "European position paper on rhinosinusitis and nasal polyps 2020", Rhinology, 58(Suppl S29), pp.1~464 (2020)
- Fokkens WJ, "EPOS", EUFOREA update on indication and evaluation of biologics in chronic rhinosinusitis with nasal polyps 2023, 2023, pp.61(3), 194~202
- Harb H, "Mechanisms of dupilumab", Clin Exp Allergy, 50(1), pp.5~14 (2020)
- Bachert C, "Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24and LIBERTY NP SINUS-52): Results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials", Lancet, 394(10209), pp.1638~1650 (2019)
- Jo CE, "Facial and neck erythema associated with dupilumab treatment : A systematic review", J Am Acad Dermatol, 84(5), pp.1339~1347 (2021)
- Chromy D, "Dupilumab-induced skin-associated side effects in patients with chronic rhinosinusitis with nasal polyposis", J Dermatol, 50(1), pp.89~93 (2023)
- Chiricozzi A, "Dupilumab-associated ocular adverse events are predicted by low tear break-up time and correlate with high IL-33 tear concentrations in patients with atopic dermatitis", Exp Dermatol, 32(9), pp.1531~1537 (2023)